SYNERGY™ XD

Everolimus-Eluting Platinum Chromium Coronary Stent System

SYNERGY™ BP Stent Clinical Overview

The SYNERGY Bioabsorbable Polymer (BP) Stent Platform has been studied in over 35,000 patients across various patient and lesion complexities.

Heal With Confidence: Leading in Complex Patients

 

Consistently Low ST Rates

Kang Network Meta-Analysis
SCAAR Registry
 

Leading On Studying Short DAPT

 
 

ARC definite/probable ST
vs. performance goal4

0.2% ST Rate

ARC definite/probable ST vs. performance goal chart

Adjusted death/MI with 3-month DAPT
vs. historical control5

Non-Inferior

Adjusted death/MI with 3-month DAPT vs. historical control chart
 
 

All patients6

All patients chart

1-month DAPT discontinuation cohort§§ 6

1-month DAPT discontinuation cohort
 

Excellent Outcomes in Long Lesions

  • 100 patients
  • 15 sites across US, Europe, and New Zealand
  • 100% B2/C lesions
  • 27% diabetes mellitus
 
 
 
 
 
 

 
Xtra Deliverability

Xtra Deliverability

Learn about the continued advancement in deliverability that SYNERGY XD offers

Button
SYNERGY XD 48 mm

SYNERGY XD 48 mm

Discover the FIRST and ONLY 48 mm DES available in the U.S.

Button
Optimal Healing

Optimal Healing

Find out how synchronous drug elution and polymer absorption enables early healing

Button
 
 
Top